Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Vaxart, Inc.
Vaxart, Inc. News
Jul 24, 2025 - globenewswire.com
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
Jul 8, 2025 - globenewswire.com
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
Jun 13, 2025 - globenewswire.com
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
Jun 11, 2025 - globenewswire.com
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
Vaxart, Inc. Quantitative Score
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Vaxart, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Vaxart, Inc. Financials
Table Compare
Compare VXRT metrics with: | |||
|---|---|---|---|
Earnings & Growth | VXRT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | VXRT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | VXRT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | VXRT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Vaxart, Inc. Income
Vaxart, Inc. Balance Sheet
Vaxart, Inc. Cash Flow
Vaxart, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Vaxart, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 1.1080 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 1.108 | Quarterly |
Historical Market Cap
Shares Outstanding
Vaxart, Inc. Executives
| Name | Role |
|---|---|
| Mr. Steven Lo | President, Chief Executive Officer & Director |
| Dr. James F. Cummings M.D. | Chief Medical Officer |
| Dr. Sean N. Tucker Ph.D. | Senior Vice President & Chief Scientific Officer |
| Mr. Phillip Eric Lee | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Steven Lo | President, Chief Executive Officer & Director | Male | 1967 | 879.33K |
| Dr. James F. Cummings M.D. | Chief Medical Officer | 1967 | 679.94K | |
| Dr. Sean N. Tucker Ph.D. | Senior Vice President & Chief Scientific Officer | 1968 | 622.44K | |
| Mr. Phillip Eric Lee | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | Male | 1988 | -- |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer | 1972 | -- |
Vaxart, Inc. Insider Trades
| Date | 29 Jul |
| Name | Watson W. Mark |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 10000 |
| Date | 13 Jun |
| Name | Finney Kevin |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 6103 |
| Date | 13 Jun |
| Name | Finney Kevin |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 36392 |
| Date | 13 Jun |
| Name | Watson W. Mark |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 16000 |
| Date | 13 Jun |
| Name | Watson W. Mark |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 95400 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 29 Jul | Watson W. Mark | Director | Acquired | P-Purchase | 10000 |
| 13 Jun | Finney Kevin | Director | Acquired | A-Award | 6103 |
| 13 Jun | Finney Kevin | Director | Acquired | A-Award | 36392 |
| 13 Jun | Watson W. Mark | Director | Acquired | A-Award | 16000 |
| 13 Jun | Watson W. Mark | Director | Acquired | A-Award | 95400 |